Acyclovir
- Generic Name
- Acyclovir
- Brand Names
- Sitavig, Xerese, Zovirax
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N5O3
- CAS Number
- 59277-89-3
- Unique Ingredient Identifier
- X4HES1O11F
- Background
Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.
Acyclovir was granted FDA approval on 29 March 1982.
- Indication
An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older. Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox. An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutan...
- Associated Conditions
- Bell's Palsy, Chickenpox, Cytomegalovirus (CMV) Infections, Herpes Simplex Infections, Herpes Zoster, Herpes simplex encephalitis, Herpes simplex of the oral-labial, Herpes simplex type I reactivation, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis, VZV re-activation, Acute Genital herpes, Acute Herpes labialis, Acute Herpetic keratitis, Severe Genital herpes
- Associated Therapies
- -
Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-01
- Target Recruit Count
- 180
- Registration Number
- NCT00000953
- Locations
- 🇺🇸
Med College of Georgia, Augusta, Georgia, United States
🇺🇸UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Veterans Administration Med Ctr, Martinez, California, United States
Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth
- Conditions
- First Posted Date
- 2000-08-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 66
- Registration Number
- NCT00006135
- Locations
- 🇺🇸
University of Texas Southwestern Medical School, Dallas, Texas, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Tulane University Medical Center, New Orleans, Louisiana, United States
Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System
- Conditions
- First Posted Date
- 2000-08-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 132
- Registration Number
- NCT00006132
- Locations
- 🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸University of Arkansas, Little Rock, Arkansas, United States
Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 25
- Registration Number
- NCT00004644
Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and Mouth
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00004757
Herpetic Eye Disease Study (HEDS) II
- Conditions
- First Posted Date
- 1999-09-24
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- National Eye Institute (NEI)
- Registration Number
- NCT00000139
- Locations
- 🇺🇸
Wills Eye Hospital, Cornea Clinic, Philadelphia, Pennsylvania, United States
🇺🇸Department of Ophthalmology, The Mount Sinai Medical Center, New York, New York, United States
🇺🇸Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
Herpetic Eye Disease Study (HEDS) I
- Conditions
- First Posted Date
- 1999-09-24
- Last Posted Date
- 2009-09-17
- Lead Sponsor
- National Eye Institute (NEI)
- Registration Number
- NCT00000138
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.